首页> 中文期刊> 《中国药理学通报》 >GSK-3β参与神经精神疾病的研究进展

GSK-3β参与神经精神疾病的研究进展

         

摘要

糖原合成酶激酶-3β( glycogen synthase kinase-3β,GSK-3β)是一种丝氨酸/苏氨酸激酶,最初发现是糖原合成过程中的关键酶。在神经系统中,GSK-3β通过转录激活、细胞增殖与细胞分化参与神经系统的多种病理生理过程。 GSK-3β活性异常引起其下游的信号蛋白及基因表达异常,导致与其底物相关的如双极紊乱、精神分裂症、阿尔采末病及疼痛等多种神经精神疾病的发生。近年来, GSK-3β已成为基础和临床研究的热点,也逐渐成为众多疾病的治疗靶点。该文就GSK-3β参与神经精神疾病的机制做简要论述。%Glycogen synthase kinase-3β( GSK-3β) is a serine-threonine kinase,which was originally identified as a key regula-tor of glycogen metabolism. In nervous system, GSK-3β partici-pates in many central and peripheral nervous system physiological processes through transcription,cell proliferation and differentia-tion. The abnormal activity of GSK-3βinduces downstream signa-ling molecules and gene expression abnormalities,which are in-volved in some neuropsychiatric disorders such as schizophrenia, bipolar disorder,Alzheimer's disease,and pain. In recent years, lots of basic and clinic researches focus on GSK-3β,which might gradually become critical theraptic target of many diseases. The article mainly reviews the mechanisms involved in abnormal acti-vation of GSK-3β related neuropsychiatric disorders.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号